MX2009012789A - Composiciones farmaceuticas no acuosas estables. - Google Patents

Composiciones farmaceuticas no acuosas estables.

Info

Publication number
MX2009012789A
MX2009012789A MX2009012789A MX2009012789A MX2009012789A MX 2009012789 A MX2009012789 A MX 2009012789A MX 2009012789 A MX2009012789 A MX 2009012789A MX 2009012789 A MX2009012789 A MX 2009012789A MX 2009012789 A MX2009012789 A MX 2009012789A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
aqueous pharmaceutical
stable non
hyperglycaemia
semi
Prior art date
Application number
MX2009012789A
Other languages
English (en)
Inventor
Svend Havelund
Simon Bjerregaard Jensen
Florian Anders Foeger
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2009012789A publication Critical patent/MX2009012789A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas no acuosas estables en almacenamiento, y al uso de las mismas en métodos de tratar diabetes e hiperglicemia, que comprende polipéptido activo deshidratado que comprende lo-loo aminoácidos y por lo menos un solvente orgánico prótico semipolar.
MX2009012789A 2007-06-01 2008-05-30 Composiciones farmaceuticas no acuosas estables. MX2009012789A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07109435 2007-06-01
EP07114524 2007-08-17
PCT/EP2008/056689 WO2008145730A1 (en) 2007-06-01 2008-05-30 Stable non-aqueous pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2009012789A true MX2009012789A (es) 2009-12-10

Family

ID=39764679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012789A MX2009012789A (es) 2007-06-01 2008-05-30 Composiciones farmaceuticas no acuosas estables.

Country Status (11)

Country Link
US (3) US20100190706A1 (es)
EP (4) EP2164458A1 (es)
JP (2) JP5675347B2 (es)
KR (1) KR20100017667A (es)
CN (1) CN101677944A (es)
AU (1) AU2008257505B2 (es)
BR (1) BRPI0812354A2 (es)
CA (1) CA2716159A1 (es)
MX (1) MX2009012789A (es)
RU (1) RU2472492C2 (es)
WO (2) WO2008145730A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663074A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
EP2164458A1 (en) * 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
WO2011033019A1 (en) * 2009-09-16 2011-03-24 Novo Nordisk A/S Stable non-aqueous liquid pharmaceutical compositions comprising an insulin
US9445992B2 (en) 2009-11-25 2016-09-20 Arisgen Sa Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion
CA2786953A1 (en) * 2010-01-12 2011-07-21 Florian Anders Foeger Pharmaceutical compositions for oral administration of insulin peptides
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
EP2608771B1 (en) * 2010-08-23 2018-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions for gastric delivery of active agents
EP2526971A1 (en) 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
ES2594303T3 (es) 2012-04-11 2016-12-19 Novo Nordisk A/S Formulaciones de insulina
US8853189B2 (en) 2012-05-31 2014-10-07 Prima Innovations, Llc Antispasmodic 1,2-Diols and 1,2,3-triols
WO2014124096A1 (en) * 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
PL3055325T3 (pl) 2013-10-07 2018-06-29 Novo Nordisk A/S Nowa pochodna analogu insuliny
EP2946788A1 (en) 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
EP3154568A4 (en) 2014-06-10 2018-01-24 California Institute of Technology Non-canonical insulins and their uses
ES2841933T3 (es) 2014-10-31 2021-07-12 Univ Monash Formulación en polvo
IL300839B2 (en) 2016-12-16 2024-04-01 Novo Nordisk As Pharmaceutical preparations containing insulin
EP3644964B1 (en) * 2017-06-28 2024-04-10 Children's Medical Center Corporation Promoting lung growth
CN114432424B (zh) * 2021-12-27 2023-06-27 南通联亚药业股份有限公司 一种稳定的铝塑包装去氨加压素片剂
WO2024123214A1 (ru) * 2022-12-04 2024-06-13 Общество С Ограниченной Ответственностью "Герофарм" Композиция инсулина аспарта (варианты)

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6074A (en) 1849-01-30 Machine fob making suspender-buckles
US3003A (en) * 1843-03-17 Improvement in the method of propelling vessels by means of continuous streams of water
US221A (en) 1837-06-03 Steam-boii
US4468A (en) 1846-04-25 Improvement in casting spoons
US2832685A (en) * 1952-05-24 1958-04-29 Crest Foods Co Inc Solubilization of milk proteins
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) * 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033941A (en) * 1975-12-17 1977-07-05 Eli Lilly And Company Process for purifying glucagon
JPS6030650B2 (ja) * 1979-10-26 1985-07-17 日本油脂株式会社 座薬基剤組成物
US4468221A (en) 1981-04-10 1984-08-28 Parker-Hannifin Corporation Medication infusion pump
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4719655A (en) * 1986-01-21 1988-01-19 Dean S Brooks Invalid transfer device
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5266310A (en) * 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
WO1990007522A1 (en) 1988-12-23 1990-07-12 Novo Nordisk A/S Human insulin analogues
DE3844211A1 (de) * 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
AU628674B2 (en) * 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
US5179189A (en) * 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
RU2143889C1 (ru) * 1993-02-23 2000-01-10 Генентек, Инк. Способ стабилизации полипептида, способы получения композиций полипептида и композиции
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
DE122006000015I1 (de) 1993-06-21 2006-06-29 Novo Nordisk As Asp-B28-Insulinkristalle
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
CN1056618C (zh) 1993-09-17 2000-09-20 诺沃挪第克公司 酰化的胰岛素和含有这种胰岛素的药物组合物
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US6500645B1 (en) * 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20030104981A1 (en) * 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
US5858001A (en) 1995-12-11 1999-01-12 Elan Medical Technologies Limited Cartridge-based drug delivery device
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5981489A (en) * 1996-07-18 1999-11-09 Alza Corporation Non-aqueous protic peptide formulations
ES2218622T3 (es) * 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US5957895A (en) 1998-02-20 1999-09-28 Becton Dickinson And Company Low-profile automatic injection device with self-emptying reservoir
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
US6660715B2 (en) * 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
AU2879100A (en) * 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
CN1141974C (zh) * 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
CN1160122C (zh) * 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1423136A4 (en) * 2001-08-10 2007-07-25 Epix Pharm Inc POLYPEPTIDE CONJUGATES HAVING INCREASED CIRCULATION HALF-VIES
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en) * 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
EP1456371A1 (en) * 2001-12-05 2004-09-15 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
UA46669C2 (uk) * 2001-12-29 2005-12-15 Товариство З Обмеженою Відповідальністю "Мако" Спосіб приготування готової лікарської форми інсуліну пролонгованої дії
WO2003078538A1 (en) 2002-03-18 2003-09-25 Bespak Plc Seal material for a dispensing apparatus
WO2003105768A2 (en) * 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US7563807B2 (en) * 2002-09-17 2009-07-21 Merck & Co. Inc. Removal of aldehyde impurity by reactive polystyrene resini
PL1633391T3 (pl) * 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
WO2005012347A2 (en) * 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
RU2421238C2 (ru) * 2003-11-20 2011-06-20 Ново Нордиск А/С Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
CN102816228A (zh) 2003-12-03 2012-12-12 诺和诺德公司 单链胰岛素
WO2005058961A2 (en) * 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
CN101084016A (zh) * 2004-04-15 2007-12-05 克艾思马有限公司 能够容易穿透生物学障碍的组合物
JP2007537274A (ja) * 2004-05-10 2007-12-20 ナステック ファーマスーティカル カンパニー インク． 副甲状腺ホルモンの粘膜送達を増強するための組成物及び方法
PL1773878T3 (pl) * 2004-07-19 2015-07-31 Biocon Ltd Koniugaty insulina-oligomer, ich formulacje i zastosowania
EP1781324A2 (en) 2004-08-20 2007-05-09 Novo Nordisk A/S Pharmaceutically active insulin receptor-modulating molecules
US20080200383A1 (en) * 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
CN101212947A (zh) * 2005-06-30 2008-07-02 阿斯利康(瑞典)有限公司 环境检测器
KR20080064171A (ko) * 2005-10-20 2008-07-08 나스텍 파마수티컬 컴퍼니 인코포레이티드 속효성 인슐린의 비강내 투여
CA2663074A1 (en) 2006-09-22 2008-03-27 Novo Nordisk A/S Protease resistant insulin analogues
EP2164458A1 (en) * 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
WO2010060667A1 (en) * 2008-11-28 2010-06-03 Novo Nordisk A/S Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides

Also Published As

Publication number Publication date
US20100144592A1 (en) 2010-06-10
WO2008145732A1 (en) 2008-12-04
KR20100017667A (ko) 2010-02-16
BRPI0812354A2 (pt) 2015-01-27
JP5628026B2 (ja) 2014-11-19
EP2497462A1 (en) 2012-09-12
AU2008257505B2 (en) 2013-05-16
RU2009146883A (ru) 2011-07-20
RU2472492C2 (ru) 2013-01-20
CN101677944A (zh) 2010-03-24
EP2164459A1 (en) 2010-03-24
US20100190706A1 (en) 2010-07-29
EP2164458A1 (en) 2010-03-24
WO2008145730A1 (en) 2008-12-04
EP2514407A1 (en) 2012-10-24
CA2716159A1 (en) 2008-12-04
JP2010529956A (ja) 2010-09-02
JP5675347B2 (ja) 2015-02-25
AU2008257505A1 (en) 2008-12-04
US20140349924A1 (en) 2014-11-27
JP2010529004A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
MX2009012789A (es) Composiciones farmaceuticas no acuosas estables.
MX2014015257A (es) Proteinas del factor 21 de crecimiento de fibroblasto.
EA201492064A1 (ru) Варианты фактора роста фибробластов 21
UA104605C2 (uk) Аналоги глюкагону
GEP20146056B (en) Acylated glucagon analogues
WO2013006486A3 (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
MY158890A (en) Pegylated insulin lispro compounds
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
BRPI0916515B8 (pt) polipeptídeo de fator estimulante de colônias de granulócitos bovino (bg-csf), formulação farmacêutica e composição compreendendo o mesmo
NZ596037A (en) Fgf21 mutants and uses thereof
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
AR092076A1 (es) Proteinas homodimericas
CA2818969A1 (en) Improved n-terminal capping modules for designed ankyrin repeat proteins
WO2009073618A3 (en) Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
EA201490521A1 (ru) Варианты фактора роста фибробластов 21
MX355457B (es) Fsh recombinante que incluye alfa, 2-3- y alfa 2,6-sialilacion.
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
WO2011008823A3 (en) Peptide-mediated non-covalent delivery of active agents across the blood brain barrier
EA201170878A1 (ru) Полипептиды с ксиланазной активностью
WO2011008495A3 (en) Arginase formulations and methods
EP2502618A3 (en) Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
MX342039B (es) Composiciones y usos de materiales con actividad antimicrobiana elevada y toxicidad baja referencia cruzada a solicitudes previas.
WO2006138099A3 (en) Bone morphogenetic protein formulations
PH12015502102A1 (en) Reducing proinflammatory response
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions

Legal Events

Date Code Title Description
FG Grant or registration